Gossamer Bio, Inc. - GOSS STOCK NEWS

Gossamer Bio, Inc. (NASDAQ: GOSS) has appointed Bryan Giraudo as Chief Operating Officer, maintaining his role as Chief Financial Officer. He joined Gossamer in May 2018 and has significantly contributed to the company's financial and organizational strength. Giraudo's promotion reflects his expanding leadership role. Before joining Gossamer, he was a Senior Managing Director at SVB Leerink and a Managing Director at Merrill Lynch's Global Healthcare Investment Banking Group. Gossamer Bio focuses on therapeutics in immunology, inflammation, and oncology.

Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q2 2021 financial results, highlighting a net loss of $59.8 million, or $0.80 per share, an improvement from a net loss of $66.9 million, or $1.00 per share in Q2 2020. As of June 30, 2021, cash, cash equivalents, and marketable securities totaled $405.9 million, projected to fund operations through H2 2023. Key clinical updates include ongoing Phase 2 studies for seralutinib and GB004, with safety data showing promise in PAH treatment. However, Gossamer will discontinue further development of GB1275.

Gossamer Bio (Nasdaq: GOSS) announced it will report its Q2 2021 financial results on August 9, 2021. The live conference call will take place at 4:30 p.m. ET, where management will discuss the results and provide a corporate update. Investors can join the call via domestic at (833) 646-0603 or international at (929) 517-9782. A replay will be available for 30 days on their website, www.gossamerbio.com. Gossamer is focused on developing therapeutics in immunology, inflammation, and oncology.

Gossamer Bio (Nasdaq: GOSS) announced its participation in the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), taking place from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present findings from the completed Phase 1b clinical trial for GB004, an oral gut-target HIF-1α stabilizer, focusing on target engagement and pharmacodynamic biomarkers in patients with mild-to-moderate ulcerative colitis. The presentation and poster will later be accessible on Gossamer Bio's website.

Gossamer Bio, Inc. (Nasdaq: GOSS) has announced the promotion of Richard Aranda, M.D., to Chief Medical Officer. Dr. Aranda, who has been with Gossamer since February 2018, previously served as Senior Vice President and Head of Clinical Development. His leadership is seen as crucial for the company's success in drug development, having extensive experience in clinical roles at Receptos and Novo-Nordisk. Gossamer Bio focuses on developing therapeutics in immunology, inflammation, and oncology, aiming to enhance patient care in these areas.

Gossamer Bio (Nasdaq: GOSS) has announced the appointment of Dr. Sandra Milligan to its Board of Directors. Dr. Milligan brings extensive experience from her role as Head of Research and Development at Organon, and previous positions at Merck and Genentech. CEO Faheem Hasnain praised her knowledge as invaluable for Gossamer’s mission to develop novel therapies in immunology, inflammation, and oncology. With a strong educational background in biology, psychology, medicine, and law, Dr. Milligan is expected to contribute significantly to the company's strategic direction.

Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q1 2021 financial results, noting a net loss of $57.6 million or $0.78 per share, compared to a net loss of $54.1 million or $0.87 per share in Q1 2020. Cash and equivalents stood at $453.3 million, sufficient to fund operations into 2023. Key clinical updates include ongoing trials for seralutinib in pulmonary arterial hypertension, GB004 for inflammatory bowel disease, and GB1275 for solid tumors, with results expected in 2022. The company also announced leadership promotions.

Gossamer Bio, Inc. (GOSS) announced that Chief Scientific Officer Luisa Salter-Cid will resign effective April 30, 2021. Laura Carter, previously Senior Vice President of Research & Translational Biology, will succeed her. Chairman and CEO Faheem Hasnain acknowledged Salter-Cid's contributions in developing the pre-clinical pipeline and welcomed Carter, highlighting her extensive experience in immunology and clinical development. Carter's background includes leadership roles in various biopharmaceutical firms, enhancing her capability to drive Gossamer’s clinical programs forward.

Gossamer Bio (Nasdaq: GOSS) has promoted Caryn Peterson to Executive Vice President, Regulatory Affairs, effective immediately. In her new role, Peterson will lead the company's regulatory and quality functions and develop global regulatory strategies for clinical and pre-clinical programs. She has been with Gossamer since 2018, previously serving as Senior Vice President, Regulatory & Quality. CEO Faheem Hasnain highlighted her strategic acumen and strong relationships with regulatory agencies as vital for advancing Gossamer's clinical portfolio, which includes candidates like seralutinib and GB004.